Application of the 2022 American Thoracic/European Respiratory Society/Japanese Respiratory Society/Associatión Latinoamericana de Tórax (ATS/ERS/JRS/ALAT) idiopathic pulmonary fibrosis and progressive pulmonary fibrosis clinical practice guideline to a Canadian population: An opinion piece

References

• Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. doi:10.1164/rccm.202202-0399ST.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. doi:10.1164/rccm.201807-1255ST.
   PubMed Web of Science ®Google Scholar
• Troy LK, Grainge C, Corte TJ, et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med. 2020;8(2):171–181. doi:10.1016/S2213-2600(19)30342-X.
   PubMed Web of Science ®Google Scholar
• Kheir F, Uribe Becerra JP, Bissell B, et al. Use of a genomic classifier in patients with interstitial lung disease: a systematic review and meta-analysis. Ann Am Thorac Soc. 2022;19(5):827–832.
   PubMed Web of Science ®Google Scholar
• Bédard Méthot D, Leblanc É, Lacasse Y. Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Chest. 2019;155(1):33–43. doi:10.1016/j.chest.2018.07.038.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727. doi:10.1056/NEJMoa1908681.
   PubMed Web of Science ®Google Scholar
• Khor YH, Farooqi M, Hambly N, et al. Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions. Am J Respir Crit Care Med. 2023;207(1):102–105. doi:10.1164/rccm.202205-0910LE.
   PubMed Web of Science ®Google Scholar
• Hambly N, Farooqi MM, Dvorkin-Gheva A, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60(4):2102571. doi:10.1183/13993003.02571-2021.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Danoff SK, Woodhead FA, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023;11(1):87–96. doi:10.1016/S2213-2600(22)00260-0.
   PubMed Web of Science ®Google Scholar
• Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–157. doi:10.1016/S2213-2600(19)30341-8.
   PubMed Web of Science ®Google Scholar
• Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476–486.
   PubMed Web of Science ®Google Scholar
• Canada’s health care system. 2023. https://www.canada.ca/en/health-canada/services/canada-health-care-system.html.
   Google Scholar
• Fortin M, Liberman M, Delage A, et al. Transbronchial lung cryobiopsy and surgical lung biopsy: a prospective multi-centre agreement clinical trial (CAN-ICE). Am J Respir Crit Care Med. 2023;207(12):1612–1619. doi:10.1164/rccm.202209-1812OC.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4(5):381–389. doi:10.1016/S2213-2600(16)00067-9.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. doi:10.1056/NEJMoa1402584.
   PubMed Web of Science ®Google Scholar
• Johannson KA, Lethebe BC, Assayag D, et al. Travel distance to subspecialty clinic and outcomes in patients with fibrotic interstitial lung disease. Ann Am Thorac Soc. 2022;19(1):20–27.
   PubMed Web of Science ®Google Scholar
• Grewal JS, Morisset J, Fisher JH, et al. Role of a regional multidisciplinary conference in the diagnosis of interstitial lung disease. Ann Am Thorac Soc. 2019;16(4):455–462. doi:10.1513/AnnalsATS.201811-794OC.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Tan B, Fell CD, et al. The Canadian registry for pulmonary fibrosis: design and rationale of a national pulmonary fibrosis registry. Can Respir J. 2016;2016:3562923–3562927. doi:10.1155/2016/3562923.
   PubMed Web of Science ®Google Scholar